Prytime Medical designs, develops, and commercializes minimally invasive REBOA solutions for truncal hemorrhage control. Its core products include the ER-REBOA PLUS and the pREBOA-PRO™ partial REBOA catheter. The pREBOA-PRO™ is the first FDA-cleared REBOA catheter designed specifically for true partial REBOA. The company reports its products have been used in 7,500 clinical cases worldwide. Prytime is led by CEO David Spencer and is based in San Antonio, Texas. The company intends to use proceeds from its recent financing to commercialize its new products.

Total raised

$6M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2021